Ilsung Pharmaceuticals Co., Ltd.
KRX:003120.KS
16720 (KRW) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 78,053.232 | 61,247.847 | 42,089.836 | 40,600.732 | 48,411.628 | 61,652.595 | 67,043.035 | 67,463.384 | 61,745.116 | 62,828.921 | 62,807.49 | 77,160.761 | 68,191.775 | 68,594.693 | 71,467.214 | 79,870.404 | 78,833.528 |
| Cost of Revenue
| 43,337.407 | 33,312.709 | 25,954.755 | 27,418.605 | 30,246.266 | 39,059.003 | 40,798.908 | 42,473.74 | 39,584.133 | 41,508.317 | 41,725.424 | 55,893.802 | 43,732.577 | 44,087.61 | 40,698.613 | 42,842.196 | 37,028.404 |
| Gross Profit
| 34,715.825 | 27,935.138 | 16,135.081 | 13,182.128 | 18,165.362 | 22,593.592 | 26,244.127 | 24,989.644 | 22,160.983 | 21,320.603 | 21,082.066 | 21,266.959 | 24,459.198 | 24,507.083 | 30,768.601 | 37,028.208 | 41,805.124 |
| Gross Profit Ratio
| 0.445 | 0.456 | 0.383 | 0.325 | 0.375 | 0.366 | 0.391 | 0.37 | 0.359 | 0.339 | 0.336 | 0.276 | 0.359 | 0.357 | 0.431 | 0.464 | 0.53 |
| Reseach & Development Expenses
| 1,523.689 | 1,512.384 | 99.083 | 109.21 | 93.488 | 131.815 | 303.957 | 237.142 | 318.931 | 212.553 | 417.762 | 881.331 | 1,070.171 | 1,167.759 | 1,117.025 | 544.196 | 415.478 |
| General & Administrative Expenses
| 2,614.375 | 1,606.776 | 1,478.321 | 1,405.302 | 1,629.454 | 2,079.733 | 2,339.951 | 2,747.506 | 2,689.12 | 2,907.284 | 2,776.651 | 2,776.781 | 2,503.564 | 2,378.294 | 2,314.77 | 2,517.907 | 2,998.271 |
| Selling & Marketing Expenses
| 20,166.36 | 13,174.341 | 7,669.888 | 4,576.657 | 7,608.068 | 7,885.108 | 10,488.739 | 9,090.822 | 6,709.222 | 5,816.481 | 6,366.744 | 5,556.189 | 6,596.947 | 6,476.578 | 6,124.793 | 5,682.471 | 6,470.976 |
| SG&A
| 40,948.189 | 14,781.117 | 9,148.209 | 5,981.959 | 9,237.522 | 9,964.841 | 12,828.69 | 11,838.328 | 9,398.342 | 8,723.765 | 9,143.395 | 8,332.97 | 9,100.511 | 8,854.872 | 8,439.563 | 8,200.378 | 9,469.247 |
| Other Expenses
| -138.943 | 10,344.378 | 8,685.2 | 9,038.743 | 10,091.47 | -343.243 | 147.476 | -226.874 | 124,653.48 | 894.364 | 8,539.031 | 47,047.886 | 42,547.877 | 173.555 | 310.781 | 421.344 | 2,536.162 |
| Operating Expenses
| 42,471.878 | 26,637.879 | 17,932.492 | 15,129.912 | 19,422.48 | 20,335.237 | 23,653.717 | 22,535.196 | 19,571.422 | 18,889.929 | 19,710.085 | 19,946.835 | 20,223.72 | 20,019.156 | 18,633.597 | 18,793.241 | 21,353.257 |
| Operating Income
| -7,756.053 | 140,224.675 | 1,628.334 | -298.556 | 226.767 | 2,258.355 | 2,590.41 | 2,454.448 | 2,589.561 | 2,430.674 | 1,371.981 | 1,320.124 | 4,470.46 | 4,487.927 | 12,135.004 | 18,234.968 | 20,451.867 |
| Operating Income Ratio
| -0.099 | 2.289 | 0.039 | -0.007 | 0.005 | 0.037 | 0.039 | 0.036 | 0.042 | 0.039 | 0.022 | 0.017 | 0.066 | 0.065 | 0.17 | 0.228 | 0.259 |
| Total Other Income Expenses Net
| -13,588.883 | -2,251.813 | -3,151.667 | 4,715.473 | 8,952.376 | 2,328.406 | 1,991.796 | 2,532.995 | 128,429.744 | 5,476.047 | 9,603.595 | 46,974.717 | 42,743.185 | 4,586.655 | -627.997 | 29,883.529 | 5,665.275 |
| Income Before Tax
| -21,344.936 | 137,972.862 | -1,523.333 | 4,416.917 | 9,179.143 | 4,586.761 | 4,582.206 | 4,987.443 | 131,019.305 | 7,906.722 | 10,975.576 | 48,294.841 | 46,978.663 | 9,074.582 | 11,507.007 | 48,118.496 | 26,117.142 |
| Income Before Tax Ratio
| -0.273 | 2.253 | -0.036 | 0.109 | 0.19 | 0.074 | 0.068 | 0.074 | 2.122 | 0.126 | 0.175 | 0.626 | 0.689 | 0.132 | 0.161 | 0.602 | 0.331 |
| Income Tax Expense
| -404.043 | 32,731.67 | -155.822 | 1,196.661 | 2,460.593 | 1,641.232 | 1,953.553 | 1,970.201 | 32,165.374 | 3,872.158 | 3,020.558 | 11,843.105 | 11,895.656 | 2,777.117 | 3,457.22 | 13,955.437 | 8,417.294 |
| Net Income
| -20,940.893 | 108,669.346 | -1,367.51 | 3,220.257 | 6,718.55 | 2,945.529 | 2,628.653 | 3,017.242 | 98,853.931 | 4,034.564 | 7,955.018 | 36,451.736 | 35,083.007 | 6,297.465 | 8,049.787 | 34,163.059 | 17,699.848 |
| Net Income Ratio
| -0.268 | 1.774 | -0.032 | 0.079 | 0.139 | 0.048 | 0.039 | 0.045 | 1.601 | 0.064 | 0.127 | 0.472 | 0.514 | 0.092 | 0.113 | 0.428 | 0.225 |
| EPS
| -2,994.34 | 2,906.49 | -178.32 | 419.91 | 971.73 | 438.4 | 391.2 | 449 | 14,713 | 600.4 | 1,175.4 | 5,281 | 4,824.4 | 740.2 | 843 | 2,809.2 | 1,340 |
| EPS Diluted
| -2,994.34 | 2,906.49 | -178.32 | 419.91 | 971.73 | 438.4 | 391.2 | 449 | 14,713 | 600.4 | 1,175.4 | 5,281 | 4,824.4 | 740.2 | 843 | 2,809.2 | 1,340 |
| EBITDA
| -4,907.02 | 143,318.72 | 4,702.174 | 2,760.178 | 3,311.639 | 6,890.437 | 7,804.027 | 5,474.199 | 133,972.905 | 10,600.719 | 14,929.615 | 51,691.437 | 50,418.562 | 11,443.444 | 19,231.164 | 26,602.06 | 27,553.756 |
| EBITDA Ratio
| -0.063 | 2.34 | 0.112 | 0.068 | 0.068 | 0.112 | 0.116 | 0.081 | 2.17 | 0.169 | 0.238 | 0.67 | 0.739 | 0.167 | 0.269 | 0.333 | 0.35 |